论文部分内容阅读
三苯氧胺是目前乳腺癌的标准激素治疗药物(辅助治疗早期乳腺癌,姑息治疗转移性乳腺癌)。toremifene是新近批准用于治疗绝经后转移性乳腺癌的一种新型抗雌激素药,该药是一种三苯氧胺类似物,化学结构与三苯氧胺相近,不同的是多一个氯原子。两者药理作用基本相同。临床前药理学研究表明,长期大剂量三苯氧胺可使大鼠发生肝癌,而toremifene则不然。不过该差异并无实际临床意义,因未发现用三苯氧胺的病人肝癌危险增加。一个世界范围的Ⅲ期试验对该两种药物作为转移性乳腺癌第一线治疗进行了比较。该研究人群包括可测量或可估测的转移性乳腺癌
Tamoxifen is the current standard hormone therapy for breast cancer (adjunctive treatment of early breast cancer, palliative metastatic breast cancer). Toremifene is a new anti-estrogenic drug recently approved for the treatment of postmenopausal metastatic breast cancer. It is a tamoxifen analogue with a chemical structure similar to that of tamoxifen except for one more chlorine atom. The pharmacological effects of the two are basically the same. Preclinical pharmacological studies have shown that long-term high-dose tamoxifen can cause liver cancer in rats, while tormemiene is not. However, this difference has no practical clinical significance because no increased risk of liver cancer has been found in patients receiving tamoxifen. A worldwide phase III trial compared the two drugs as first-line treatment of metastatic breast cancer. The study population included measurable or predictable metastatic breast cancer